anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cardiac hypertrophy (CH) is an adaptive response to maintain cardiac function; however, persistent stress responses lead to contractile dysfunction and heart failure. Although inflammation is involved in these processes, the mechanisms that control cardiac inflammation and hypertrophy still need to be clarified. The NLRP3 inflammasome is a cytosolic multiprotein complex that mediates IL-1β production. The priming step of NLRP3 is essential for increasing the expression of its components and occurs following NF-κB activation. Hyperthyroidism triggers CH, which can progress to maladaptive CH and even heart failure. We have shown in a previous study that thyroid hormone (TH)-induced CH is linked to the upregulation of S100A8, leading to NF-κB activation. Therefore, we aimed to investigate whether the NLRP3 inflammasome is involved in TH-induced CH and its potential role in CH pathophysiology. Hyperthyroidism was induced in NLRP3 knockout (NLRP3-KO), Caspase-1-KO and Wild Type (WT) male mice of the C57Bl/6J strain, aged 8-12 weeks, by triiodothyronine (7 μg/100 g BW, i.p.) administered daily for 14 days. Morphological and cardiac functional analysis besides molecular assays showed, for the first time, that TH-induced CH is accompanied by reduced NLRP3 expression in the heart and that it occurs independently of the NLRP3 inflammasome and caspase 1-related pathways. However, NLRP3 is important for the maintenance of basal cardiac function since NLRP3-KO mice had impaired diastolic function and reduced heart rate, ejection fraction, and fractional shortening compared with WT mice.
A system and method of transmitting emergency condition using wireless sensor network are provided to cope with physical problems of users by adhering the biosensor integrated wireless sensor network communications device to the body of user. The emergency transmission system comprises the biometric sensor integration wireless sensor network communications device(430), and the relay(420) and management server(410). The biometric sensor integration wireless sensor network communications device is adhered to the body of user. The bio-information of user is transmitted from the biometric sensor integration wireless sensor network communications device through the wireless sensor network. By using the routing protocol of the wireless sensor network, the relay transmits the bio-information to the management server. The management server analyzes the bio-information and performs the emergency action.
PURPOSE/OBJECTIVE(S): Merkel cell carcinoma (MCC) radiation treatment has historically consisted of standard 1.8-2 Gy fractions treated daily over 4-6 weeks. Hypofractionated treatment regimens have demonstrated tumor control and toxicity equivalence to standard fractionation regimens for common cutaneous malignancies such as basal cell and squamous cell carcinomas. Herein we report the outcomes of hypofractionated versus standard fractionation radiotherapy for MCC at our institution.
MATERIALS/METHODS: The study involved a retrospective review of MCC patients treated with radiotherapy. Treatment characteristics and patient outcomes, including acute toxicities, disease recurrence and survival data were collected. The cumulative incidence of local and distant failures was estimated, with death as a competing risk.
RESULTS: A total of 29 treatment courses for 24 patients were included, of which 13 involved standard fractionation with curative intent, 10 involved hypofractionated radiotherapy with curative intent, and 6 involved single fraction (8 Gy) palliative radiation. Half the patients were treated to a head/neck site. A subset of patients treated adjuvantly with curative intent included 8 standard fractionation and 8 hypofractionated radiotherapy patients. No statistically significant differences in local and/or distant failure or overall survival was observed between the patient groups.
CONCLUSION: Hypofractionated radiotherapy for MCC was associated with similar treatment outcomes relative to standard fractionation. In our limited patient sample, hypofractionated radiation treatment achieved similar results with similar toxicity and fewer treatments. Further analysis of a larger patient population with longer follow up is needed to confirm treatment tolerability and efficacy.
Oral tablets taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with BPI-452080 administered once daily.
Pre-eclampsia (PE) is a hypertensive disorder characterised by systemic vascular resistance and endothelial dysfunction. It is known to influence choroidal thickness (CT). No previous studies have explored the antepartum and postpartum changes in CT with respect to the protein-creatinine ratio (PCR), a measure of proteinuria that is a clinical hallmark of PE. This study evaluated the correlations between antepartum and postpartum CT and the PCR in patients with PE. In this retrospective study, sixty-six eyes (66 patients) were analysed. The patients were divided into two groups according to the median PCR value (2.36 mg/mg): low PCR group (< 2.36 mg/mg) and high PCR group (≥ 2.36 mg/mg). Ophthalmologic clinical data were collected and assessed. We observed higher antepartum CT and higher mean arterial pressure in high PCR group than in low PCR group. Moreover, postpartum CT decreased significantly in high PCR group. In the multivariate analysis, CT changes were correlated with antepartum CT and antepartum PCR after logarithm transformation. In conclusion, a greater decrease in CT was observed in high PCR group than in low PCR group. Further, the antepartum PCR showed a correlation with the extent of CT reduction.
Formoterol fumarate inhalation solution should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition. Formoterol fumarate inhalation solution has not been studied in patients with acutely deteriorating COPD. The use of formoterol fumarate inhalation solution in this setting is inappropriate. 

Formoterol fumarate inhalation solution should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Formoterol fumarate inhalation solution has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

When beginning formoterol fumarate inhalation solution, patients who have been taking inhaled, short-acting beta2-agonists on a regular basis (e.g., four times a day) should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief of acute respiratory symptoms. When prescribing formoterol fumarate inhalation solution, the healthcare provider should also prescribe an inhaled, short-acting beta2-agonist and instruct the patient how it should be used. Increasing inhaled beta2-agonist use is a signal of deteriorating disease for which prompt medical attention is indicated. COPD may deteriorate acutely over a period of hours or chronically over several days or longer. If formoterol fumarate inhalation solution no longer controls the symptoms of bronchoconstriction, or the patient's inhaled, short-acting beta2-agonist becomes less effective or the patient needs more inhalation of short-acting beta2-agonist than usual, these may be markers of deterioration of disease. In this setting, a re-evaluation of the patient and the COPD treatment regimen should be undertaken at once. Increasing the daily dosage of formoterol fumarate inhalation solution beyond the recommended 20 mcg twice daily dose is not appropriate in this situation.
The invention belongs to the technical field of nasal pastes, and discloses a traditional Chinese medicine nasal paste for inducing resuscitation and a preparation method thereof. The plant essential oil consists of 20-25 parts of musk essential oil, 20-25 parts of borneol essential oil, 20-25 parts of storax essential oil, 10-15 parts of menthol and 20-25 parts of ligusticum wallichii volatile oil in parts by mass. The outer layer of the plant essential oil is wrapped by a protective film. The back plaster consists of a plaster and medical non-woven fabrics. The lower layer of the medical non-woven fabric is fixed with plant essential oil the outer layer of which is wrapped with a protective film. The medical non-woven fabric and the plant essential oil of which the outer layer is wrapped by the protective film are fixed by an adhesive. The invention volatilizes a plurality of natural essential oil components of musk essential oil, borneol essential oil, storax essential oil, menthol and ligusticum wallichii volatile oil into nostrils, thereby not only effectively refreshing and inducing resuscitation, but also having high safety due to the natural essential oil components, being also used by children and having long persistence.
Paraoxonase 1 (PON1) is one of the most significant antioxidative enzymes associated with high-density lipoprotein (HDL). It has been proved that is involved in the pathogenesis of many diseases including chronic kidney disease (CKD). The association between PON1 and CKD seems to be mutual, such that the disease produces a significant decrease in PON1 activity levels, while the genetics of PON1 may affect the risk of susceptibility to CKD. Recent studies reveal that the decrease in serum PON1 activity observed in non-dialyzed and dialyzed CKD patients as well as in renal transplant (RT) patients is linked to an increased vulnerability to atherosclerosis. We intend to summarize current literature concerning PON1 activity in CKD, highlighting on the main determinants of PON1 activity, its association with oxidative stress, the impact of its genetic polymorphism on the disease development, the effect of drugs and nutritional state. Furthermore, evidence supporting the implication of reduced PON1 activity in the incident of cardiovascular disease in CKD patients, is also examined. It appears that despite the lack of standardization of PON1 activity measurement, PON1 remains a valuable biomarker for the researchers through the last decades, which contributes to the assessment of the antioxidant status having prognostic benefit on adverse clinical outcomes at various stages and etiologies of kidney disease.
The invention provides bionic antibacterial and antioxidant nanoparticles based on zanthoxylum bungeanum maxim extract and a preparation method thereofA preparation method and application thereof, belonging to the technical field of medicine preparation. The invention provides a compound shown in formula I, or a salt or a stereoisomer thereof. The invention also provides nanoparticles prepared from the compound shown in the formula I and the antibacterial peptide. The invention performs hydroformylation on a compound extracted from zanthoxylum bungeanum maxim to obtain a new compound which has antioxidant capacity. The antibacterial peptide-compound nano particles prepared by mixing the compound and the antibacterial peptide have good biocompatibility and synergistic antioxidant and antibacterial capabilities. The nano particles can controllably release the antibacterial peptide according to the wound microenvironment, can effectively remove bacteria caused by infection and adjust the oxidative stress state of the wound, can promote the rapid healing of the wound, simultaneously plays a role in promoting the healing of the wound in a synergistic manner, and has important application prospect in promoting the healing of the wound clinically.
Patients receive Prednisolone 1% 1gtt qid x 4 weeks. If the intraocular pressure (IOP) after the 4 weeks is \> or equal to 21 mmHg, then IVTA will be withheld. If the IOP \< 21mmHg, then patients will receive an injection of IVTA.
The primary endpoint for the study is PFS6mo by RECIST 1.1. The sample size calculation is based on a Simon Two-Stage design with incorporation of early stopping rules for safety and futility (See section 9 for statistical considerations). The Investigators will enroll up to 35 patients on the study to obtain 28 evaluable patients for the primary endpoint. Safety of the combination will be evaluated after the first six patients complete the DLT observation period of 9 weeks. This lengthy DLT period is designed to capture safety and toxicity profile, understanding that immune-related toxicities from checkpoint inhibitors may not emerge immediately. This will also ensure adequate evaluation of potential cardiac and hepatic toxicity from combination doxorubicin and checkpoint inhibitor therapy. If two or more patients experience DLT in the initial safety lead-in cohort, the regimen will be declared intolerable. Any patients who do not complete study therapy through the 9-week DLT observation period for any reasons other than toxicity will be replaced for safety lead-in assessment. If fewer than two patients experience DLT, the investigators will proceed to expansion to complete enrollment of 15 patients in Stage 1. Following enrollment of stage one, accrual will pause for analysis of efficacy. If 6 or fewer of the 15 patients are progression-free at 6 months, the investigators will halt the study for futility. If 7 or more patients are free from progression, then the investigators will proceed with enrollment of 13 additional patients to complete stage 2. the investigators are powered to detect improvement in 6-month PFS rate to 63.4% with the combination over the 43.4% historical PFS6mo.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to oncology and oncopediatry, and can be used for prediction of infertility in children and adolescents after risk-adapted treatment of Hodgkin lymphoma (HL). Initial stratification is carried out into therapeutic groups, the volume of anticancer treatment is determined. Infertility risk factors are evaluated: age of patient is 12 years and more, DAL-HD therapy is administered, dose of CP is 2 g/mand more, a dose of procarbazine 3 g/mand more, irradiation of the lymphocytes below the diaphragm, and the third risk group by the stratification of the anticancer treatment volume. Risk factors are assessed in scores according to the scoring system presented in Table 4 of the description. If the total score is 0 to 11 points inclusive, the patient is referred to the low risk group of infertility. If total score is from 12 to 23 inclusive, mean risk. If the total score is 24 points or more, the risk is high.EFFECT: method enables the stage of stratification of patients to determine the volume of primary treatment of malignant process and to anticipate the risk of occurrence of infertility after treatment by grading the sum of prognostic coefficients of factors into three groups and development of a risk scale for reducing fertility.1 cl, 5 tbl, 1 ex
To test the hypothesis of the present study, volunteers were invited to participate in two randomly assigned visits in distint days, as follows: 1) combined resistance and aerobic exercises performed in a circuit mode; and 2) a control session without exercise. In both visits, blood pressure was measured at rest and at each 15 minutes post-session during 1 hour of recovery following the exercise and non exercise control sessions. In addition, blood pressure reactivity was evaluated using a cardiovascular stressor protocol (Cold Test Pressor) before and after the experimental sessions. The relationship between post-exercise blood pressure and blood pressure reactivity to stressor test was also examined.
FIELD: medicine, neurology, phytotherapy, pharmacy. SUBSTANCE: invention relates to motherwort-base extract preparation designated for treatment of functional disturbances of the central nervous system. Invention proposes the motherwort extract-base medicinal agent comprising sugars, starch and calcium stearate as accessory substances. Agent comprises additionally polyvinylpyrrolidone, microcrystalline cellulose and aerosil and motherwort extract is used as dry powder in the following ratio of components, wt.-%: motherwort extract, 7-14; microcrystalline cellulose, 15-23; starch, 14-20; polyvinylpyrrolidone, 2-4; aerosil, 5-10; calcium stearate, 0.5-1; sugars, the balance, up to 100. The prepared tableted, simple and available medicinal formulation of medicinal agent shows the enhanced strength and simultaneous rapid decomposition in water and stability at storage. EFFECT: improved and valuable medicinal and pharmaceutical properties of preparation. 2 tbl
Participants in this group will receive both Mulligan's mobilization with movement and Spencer's muscle energy technique along with conventional therapy and home exercise plan. 3 sessions per week will be given for 4 weeks.
The difficulties those diagnosed with schizophrenia have with facial identification and identifying emotions are closely associated with the adverse symptoms of the illness. Those diagnosed with schizophrenia need to be helped in forming interpersonal relations so that they can gain the skills needed to live in society.

ın this study the investigators prepared a psychoeducation program for individuals diagnosed with schizophrenia. The program titled, "Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia" was conducted with the patients in the intervention groups once a week for ten weeks. On the other hand there were a control group which weren't be applied any intervention. The investigators applied some tests to intervention and control group three times ( before intervention, after intervention and three months after intervention). This study was conducted at three Community Mental Health Centers (CMHC's). The patients who met the study inclusion criterias were determined in these centers. Randomized psychoeducation and control groups were formed from these patients.
The ultimate goal of rehabilitation for children and adolescents with spinal cord injuries (SCIs) is to assure that they can grow up to have as productive and satisfying lives as their peers. Understanding factors associated with these outcomes of our patients after they have become adults may help to identify interventions and rehabilitation strategies that will optimize long-term outcomes. Long-term studies of adults with pediatric-onset SCI are needed to identify important outcomes, including survival, participation, health status and health-related quality of life, and life-satisfaction. Further, these outcomes need to be compared to population norms. Predictive models of important outcomes will be developed using independent factors, including demographic, impairment, functional limitation, participation, and environmental and personal factors. In addition, the impact of age at injury, upper extremity reconstruction or functional electrical stimulation implants, and the Mitrofanoff procedure on adult outcomes will be assessed. The stability of selected outcomes in comparison to normative and census data will be determined and factors associated with changes in these outcomes will be assessed.
Accumulated reactive oxygen species (ROS) and their resultant vascular dysfunction in androgenic alopecia (AGA) hinder hair follicle survival and cause permanent hair loss. However, safe and effective strategies to rescue hair follicle viability to enhance AGA therapeutic efficiency remain challenging. Herein, we fabricated a quercetin-encapsulated (Que) and polydopamine-integrated (PDA@QLipo) nanosystem that can reshape the perifollicular microenvironment to initial hair follicle regeneration for AGA treatment. Both the ROS scavenging and angiogenesis promotion abilities of PDA@QLipo were demonstrated. In vivo assays revealed that PDA@QLipo administrated with roller-microneedles successfully rejuvenated the "poor" perifollicular microenvironment, thereby promoting cell proliferation, accelerating hair follicle renewal, and facilitating hair follicle recovery. Moreover, PDA@QLipo achieved a higher hair regeneration coverage of 92.5% in the AGA mouse model than minoxidil (87.8%), even when dosed less frequently. The nanosystem creates a regenerative microenvironment by scavenging ROS and augmenting neovascularity for hair regrowth, presenting a promising approach for AGA clinical treatment.
Molecular testing for high-risk human papillomavirus (hrHPV) genotypes is important in screening for cervical cancer. In this study, we evaluated the performance of a newly developed Allplex HPV HR Detection assay in comparison with the Cobas HPV Test. A total of 1,275 cervical specimens obtained from a healthcare center between August 2021 and May 2022 were analyzed. The overall agreement for hrHPV detection was 98.4%, with higher agreement observed for HPV-16 (99.7%) and HPV-18 (99.8%) compared to other hrHPV genotypes (97.2%). Sequencing revealed that the majority of discrepancies was genotyped accurately by the Allplex HPV HR Detection assay with the exception of one false positive for HPV-16 and two false positives for other hrHPV genotypes. The Allplex HPV HR Detection assay showed almost perfect agreement with the Cobas HPV test, emphasizing its utility in hrHPV screening and monitoring.
Empagliflozin is an oral medication used to treat Type 2 diabetes. It belongs to sodium-glucose cotransporter 2 (SGLT2) inhibitors.
OX40L inhibits the generation of IL-10-producing Tr1 cells from naïve and memory CD4+ T cells induced by the immunosuppressive drugs dexamethasone and vitamin D3. This unique function of OX40L is not shared by two other costimulatory TNF-family members, GITR-ligand and 4-1BB-ligand. OX40L also strongly inhibits the generation of IL-10-producing Tr1 cells induced by two physiological stimuli provided by inducible costimulatory ligand and immature DCs and inhibits the production of IL-10 by regulatory T cells. It has thus been shown that signaling the OX40-receptor on human T cells by monoclonal antibodies, small molecules, or OX40L regulates the generation and function of IL-10 producing immunosuppressive T cells. Also provided are high throughput methods for identifying substances that promote or inhibit the generation and function of IL-10 producing T cells. Numerous disease states, such as human allergic, autoimmune, and autoimmune diseases, and cancer, may be treated by targeting OX40/OX40L.
All participants will receive 5 mg palovarotene for up to 48 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part C). Skeletally immature participants will receive weight-adjusted doses.
Participants with steroid receptor coactivator (SRC) homology 2B adapter protein 1 (SH2B1) haploinsufficiency received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.